Fuller & Thaler Asset Management Inc. Sells 396,733 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Fuller & Thaler Asset Management Inc. reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 99.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,333 shares of the medical equipment provider's stock after selling 396,733 shares during the quarter. Fuller & Thaler Asset Management Inc.'s holdings in Lantheus were worth $119,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. raised its holdings in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after purchasing an additional 435,445 shares during the period. Reinhart Partners LLC. lifted its position in shares of Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after buying an additional 123,282 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Lantheus by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after buying an additional 30,891 shares during the last quarter. Swedbank AB boosted its stake in shares of Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after acquiring an additional 385,000 shares during the period. Finally, Portolan Capital Management LLC increased its holdings in shares of Lantheus by 21.1% during the 4th quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider's stock worth $72,698,000 after acquiring an additional 141,749 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 63,109 shares of company stock worth $6,016,046. 2.00% of the stock is currently owned by company insiders.

Lantheus Stock Performance

LNTH stock opened at $101.77 on Friday. Lantheus Holdings, Inc. has a 52 week low of $65.76 and a 52 week high of $126.89. The company's 50-day simple moving average is $97.37 and its 200 day simple moving average is $95.23. The company has a market capitalization of $6.97 billion, a PE ratio of 16.93 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on LNTH shares. Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.